Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 553.15 -5.73 (1.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $558.88 | 52 Week High | $134.71 | |||
| Open | $560.88 | 52 Week Low | $73.31 | |||
| Day High | $568.67 | P/E | N/A | |||
| Day Low | $544.09 | EPS | $-1.98 | |||
| Volume | 3,208,218 | |||||
